Xlife Sciences AG (XSWX:XLS) Growth Rank: 6 (As of Jul. 07, 2026) — 50% Above Median


XSWX:XLS Xlife Sciences AG XSWX:XLS
53 GF Score
Price CHF18.15
GF Value CHF7.25
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Growth Rank?

Xlife Sciences AG XSWX:XLS 53 Growth Rank is 6 as of Jul. 07, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.25 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Xlife Sciences AG has the Growth Rank of 6.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Xlife Sciences AG Growth Rank Related Terms

XSWX:XLS vs VRTX, REGN, ALNY: Growth Rank Comparison

For the Biotechnology subindustry, Xlife Sciences AG's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xlife Sciences AG Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Growth Rank distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's Growth Rank falls into.


XSWX:XLS
53GF Score
Xlife Sciences AG XSWX:XLS
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 6 mean?
Xlife Sciences AG (XSWX:XLS) has a Growth Rank of 6 as of Jul. 07, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Xlife Sciences AG and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Xlife Sciences AG's Growth Rank has ranged from 3.00 to 6.00.
Is Xlife Sciences AG's Growth Rank too high?
Xlife Sciences AG's current Growth Rank of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 6.00. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Growth Rank compare to VRTX and REGN?
Xlife Sciences AG's Growth Rank of 6 can be compared against companies in the Biotechnology industry. Historically, Xlife Sciences AG's own Growth Rank has ranged from 3.00 to 6.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Growth Rank is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.25, compared to a current price of CHF18.15 — trading 150.3% above its estimated fair value. The current Growth Rank is 6, which is 50% above median its 10-year median of 4.00. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Growth Rank is 6 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF18.15 is trading 150.3% above its estimated GF Value™ of CHF7.25. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Growth Rank: 6 (50% above median its 10-year median of 4.00)
  • GF Value™: CHF7.25 vs. price of CHF18.15 (150.3% above fair value)
  • GF Score™: 53/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score

Get the complete analysis for XSWX:XLS

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF18.15
Price
CHF7.25
GF Value